- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06418594
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study
Some studies have shown that approximately 15% of patients with advanced hormone receptor (HR) positive breast cancer and 1/3 of triple negative breast cancer will develop brain metastasis. At present, there is no unified drug treatment standard for HER2-negative breast cancer brain metastasis (BCBM). The evidence of single traditional chemotherapy drug as the main treatment of brain metastasis is not sufficient. Some exploratory studies on HER2-negative BCBM have shown that the central nervous system objective response rate (CNS-ORR) of anti-angiogenic drugs combined with chemotherapy is around 55%-80%。 Adebrelimab (a humanized PD-L1 monoclonal antibody) specifically blocks the binding of PD-1 and PD-L1, terminates the immunosuppressive signal produced by T cells, and makes T cells re-recognize tumor cells and kill them, thereby inhibiting tumor growth. In China, Adebelizumab has been approved for using in combination with chemotherapy as a first-line treatment for extensive stage small cell lung cancer. Apatinib (a small molecule VEGFR tyrosine kinase inhibitor) mainly plays an anti-angiogenic effect in the treatment of malignant tumors by inhibiting VEGFR. Apatinib has been approved monotherapy for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma that has progressed or relapsed after at least two systematic chemotherapies, advanced liver cancer that has failed or is intolerable after at least first-line systematic treatment, and first-line treatment in patients with unresectable or metastatic hepatocellular carcinoma combined with camrelizumab.
Due to the lack of effective drug therapy for HER2-negative BCBM, a variety of treatment combinations are still being explored. We hypothesized that adebrelimab plus apatinib and etoposide is an explorable and effective treatment for HER2- negative BCBM.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jinmei Zhou, Doctor
- Phone Number: +86-010-66947250
- Email: jinzhu2714@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100071
- The Fifth Medical Center of PLA General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female, aged ≥18 years
- Expected survival time ≥3 months.
- Histologically or cytologically confirmed HER2-negative (IHC 0 or 1+; or IHC 2+ ISH negative) locally recurrent or metastatic disease
- New brain metastasis or brain metastasis progression after treatment
- HR+ advanced breast cancer with prior CDK4/6 inhibitor treatment failure or the investigator deems unsuitable for CDK4/6 inhibitors
- At least one intracranial measurable lesion as defined by RECIST V1.1 criteria;
- ECOG PS 0-2;
- Patients must have the ability to swallow oral medication;
- Prior WBRT, stereotactic radiosurgery, and surgical resection are allowed;
- Organ function levels are basically normal, and the investigator believes that the study drug can be applied:
- Voluntarily join this study, sign the informed consent, have good compliance, and are willing to cooperate with follow-up
Exclusion Criteria:
- Urgent need for local treatment of brain metastasis
- Immunohistochemistry HER2 positive (IHC 3 or IHC 2 ISH amplification)
- Previously treated with Apatinib, Avelumab, or VP-16;
- Severe dysfunction of important organs such as the heart, liver, or kidneys;
- Inability to swallow, chronic diarrhea, and intestinal obstruction, with multiple factors affecting drug administration and absorption;
- Participants diagnosed with any other malignant tumor within 5 years before this study, excluding non-melanoma skin cancer that has undergone radical treatment. Basal cell or squamous cell skin cancer or cervical carcinoma in situ and thyroid papillary carcinoma。
- Patients who allergy to any component of the drugs in this protocol; patients with history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation
- History of any cardiac disease, including: (1) arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be unsuitable for participation in this trial, etc.
- Pregnant or lactation female patients; females of childbearing age with a positive baseline pregnancy test or unwilling to take effective contraceptive measures during the entire trial period;
- According to the investigator's judgment, there are severe accompanying diseases that endanger the patient's safety or affect the completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adebrelimab+Apatinib+Etoposide
Adebrelimab: 1200mg, ivgtt,administered on the first day of each cycle, with a cycle of 21 days. Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days. Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days. |
Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
Other Names:
Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CNS-ORR
Time Frame: 2 months
|
Central nervous system objective response rate (CNS-ORR), as assessed according to the RANO-BM criteria
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CNS-PFS
Time Frame: 1 Year
|
CNS progression-free survival
|
1 Year
|
Extracranial objective response rate
Time Frame: 2 Years
|
According to recist1.1 standard, the proportion of patients whose extracranial best remission was CR or PR accounted for the total number of evaluable patients
|
2 Years
|
Extracranial progression-free survival
Time Frame: 2 Years
|
The time to the date of first documented progression or date of death from any cause, whichever came first
|
2 Years
|
OS
Time Frame: 3 Years
|
The time from the beginning of treatment to the time of death caused by any cause
|
3 Years
|
CBR
Time Frame: 2 Years
|
Clinical benefit rate: CR+PR+SD≥6 months
|
2 Years
|
DoR
Time Frame: 2 Years
|
The time from the beginning of CR or PR to the time when the tumor was first evaluated as PD or any cause of death.
|
2 Years
|
Safety
Time Frame: AE recorded from infromed consent to 28 days after treatment completion
|
Adverse events (AE), serious adverse events (SAE), and immune-related adverse events (irAE), in accordance with the NCI-CTC AE version 5.0 criteria.
AE recorded from infromed consent to 28 days after treatment completion.
|
AE recorded from infromed consent to 28 days after treatment completion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Breast Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Protein Kinase Inhibitors
- Etoposide
- Apatinib
Other Study ID Numbers
- MA-BC-II-070
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-negative Breast Cancer Brain Metastases
-
SanofiUNC Lineberger Comprehensive Cancer CenterCompletedBrain Metastases | Estrogen Receptor Negative (ER-Negative) Breast Cancer | Progesterone Receptor Negative (PR-Negative) Breast Cancer | Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast CancerUnited States
-
Sarah Sammons, MDDaiichi SankyoRecruitingBreast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast CancerUnited States
-
Yonsei UniversityRecruitingTriple Negative Breast Cancer | Metastatic Breast Cancer With HER2 PositiveKorea, Republic of
-
Sunnybrook Health Sciences CentreHarvard UniversityUnknownBreast Neoplasm | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Brain MetastasesCanada
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Dana-Farber Cancer InstituteBreast Cancer Research Foundation; Array BioPharmaCompletedAdvanced HER2-positive Breast Cancer | Brain Metastases From HER2 and Breast CancerUnited States
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); PfizerTerminatedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Breast Carcinoma Metastatic in the BrainUnited States
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
Clinical Trials on Adebrelimab
-
Henan Cancer HospitalNot yet recruiting
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Not yet recruitingAdvanced Solid TumorsChina
-
Fujian Cancer HospitalRecruitingOvarian Diseases | Ovarian NeoplasmsChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Zhongzheng XiangNot yet recruitingHead and Neck Squamous Cell Carcinoma
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingCldn18.2-positive Advanced Solid TumorChina
-
Fudan UniversityRecruitingCastration-resistant Prostate Cancer | Prostate Cancer MetastaticChina
-
Fudan UniversityJiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Hebei Medical University Fourth HospitalNot yet recruitingEsophageal Squamous Cell Carcinoma